Welcure Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: WELCURE)

Welcure Drugs & Pharmaceuticals Ltd

0.28+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Welcure Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Welcure Drugs & Pharmaceuticals Ltd share price today is 0.28, up +0.00% on NSE/BSE as of 22 June 2026. Welcure Drugs & Pharmaceuticals Ltd (WELCURE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 67.97 (Cr). The 52-week high for WELCURE share price is 15.89 and the 52-week low is 0.23. At a P/E ratio of 1.98x, WELCURE is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.18% and a debt-to-equity ratio of 0.92.

Welcure Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
0.33
Low
0.27
Volume
70.6L
Change
-9.68%

Welcure Drugs & Pharmaceuticals Ltd share price chart: -9.68% return over the past month. 52-week high ₹15.89, 52-week low ₹0.23.

Welcure Drugs & Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
0.280.280.270.2843.61L (Cr)
0.290.290.280.2857.69L (Cr)
0.290.300.280.2960.88L (Cr)
0.280.300.280.29107.46L (Cr)
0.290.300.290.2944.86L (Cr)
0.310.310.300.3051.67L (Cr)
0.310.310.300.3144.00L (Cr)
0.310.310.300.3140.61L (Cr)
0.300.310.300.3139.04L (Cr)
0.300.300.290.3067.44L (Cr)

Welcure Drugs & Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
0.280.310.270.28+0.00%
0.230.360.230.28+21.74%
0.300.310.240.24-20.00%
0.300.370.280.31+3.33%
0.420.460.310.31-26.19%
0.530.580.400.42-20.75%
0.530.640.500.53+0.00%
5.498.450.550.55-89.98%
9.3610.525.485.50-41.24%
9.4012.959.269.73+3.51%
14.2714.999.159.64-32.45%
15.8815.8912.3613.60-14.36%

AI Research Briefing

Powered by Gemini · 2026-04-13

Welcure is a micro-cap export sourcing agent with zero promoter stake and negative free cash flow; avoid until fundamentals drastically improve.

Research Confidence
4.0/10Low
MICRO-CAP DARK HORSEBreakdown: Stock is down 46.6% in the last 6 months and 97.9% from its 52-week high.P/E of 1.98x appears cheap vs industry P/E of 31.77x, but profitability and cash flow are questionable.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The stock price has fluctuated between and

CORE STORY (THE REAL GAME)

Welcure is playing the export-sourcing agent game, earning commissions without balance sheet risk. It's not a pharma innovation play. It's a micro-cap trying to scale fee-based income.

Why Now
  • No recent positive triggers
  • Dependence on volatile export orders
  • Poor financial metrics (negative FCF, zero promoter holding)
Potential Catalysts
  • Significant new export order wins
  • Improvement in profitability and cash flow
  • Acquisition by a larger player
Key Risks
  • Micro/SME cap: Liquidity risk
  • Zero promoter holding raises governance concerns
  • Negative free cash flow indicates poor cash conversion
Institutional Activity

No FII or DII holding. Promoter holding is zero.

Macro Context

Indian pharma industry is shifting towards value-led innovation but Welcure's business model is not aligned with this trend.

Cash Flow Quality

No: Free Cash Flow 5Y is ₹-222.01 Cr.

3–6 Month Outlook

Welcure's near-term prospects hinge on securing and executing export orders. Long-term sustainability is doubtful without diversification or improved profitability.

Primary Thesis Risk

Reliance on export orders and lack of promoter stake make Welcure a risky bet.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

4.18%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

2.53%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Welcure Drugs & Pharmaceuticals Ltd Valuation Check

Excellent

Price to Earnings (P/E)

1.98x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

0.00%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

361.96%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

167.29%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

214.33%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

94.95%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

193.83%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.92x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-222.01 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Welcure Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of WELCURE across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Attractive Valuation (P/E: 1.98 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (361.96%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (167.29%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (214.33% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (94.95% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (193.83% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (4.18%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (2.53%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Negative Free Cash Flow (₹-222.01 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (0.00%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Welcure Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Welcure Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
51.9/100
0
₹67.97
2.0
Average
4.18%
Poor
2.53%
Poor
0.9
Good
193.83%
Excellent
214.33%
Excellent
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Welcure Drugs & Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for WELCURE — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

167.29%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

361.96%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

214.33%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

193.83%

Compounded annual net profit growth over 5 years

Welcure Drugs & Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for WELCURE — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
0
▼ Price below SMA 50 — Short-term bearish
SMA 200
3
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
8686K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Welcure Drugs & Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Welcure Drugs & Pharmaceuticals Ltd (WELCURE) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Welcure Drugs & Pharmaceuticals Ltd

About WELCURE (Welcure Drugs & Pharmaceuticals Ltd)

Welcure Drugs & Pharmaceuticals Ltd is a dynamic player in the Indian pharmaceutical landscape, dedicated to providing access to quality medicines and innovative healthcare solutio...ns. The company operates with a commitment to improving patient outcomes and enhancing the overall well-being of communities. Welcure meticulously sources and distributes a broad spectrum of pharmaceutical products, encompassing various therapeutic areas, to meet the diverse healthcare needs of the nation. Leveraging a robust distribution network and strategic partnerships, Welcure ensures that essential medicines reach healthcare providers and patients efficiently and reliably. Moreover, the company places a strong emphasis on ethical practices, regulatory compliance, and stringent quality control measures throughout its operations, solidifying its reputation as a trusted and responsible pharmaceutical partner. Driven by a vision of contributing to a healthier India, Welcure Drugs & Pharmaceuticals Ltd continually explores opportunities to expand its product portfolio and enhance its service offerings. The company actively seeks collaborations with leading pharmaceutical manufacturers and research institutions to introduce cutting-edge therapies and innovative healthcare technologies to the Indian market. With a customer-centric approach, Welcure prioritizes building strong relationships with healthcare professionals, pharmacies, and other stakeholders to understand their evolving needs and provide tailored solutions. The company's dedicated team of professionals is committed to delivering exceptional service and support, ensuring that healthcare providers have the resources they need to deliver optimal patient care. Welcure Drugs & Pharmaceuticals Ltd is more than just a pharmaceutical distributor; it is a healthcare partner committed to making a positive impact on the lives of people across India. By focusing on quality, innovation, and accessibility, Welcure strives to address the unmet medical needs of the population and improve overall health outcomes. The company's unwavering commitment to ethical business practices, regulatory compliance, and social responsibility makes it a trusted and reliable player in the pharmaceutical industry. As Welcure continues to grow and evolve, it remains steadfast in its mission to contribute to a healthier and more prosperous India, one patient at a time.

Company Details

Symbol:WELCURE
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Chintan Didawala Ganpat
MD, CFO & Executive Director
Ms. Palak Jain
Company Secretary & Compliance Officer

WELCURE Share Price: Frequently Asked Questions

What is the current share price of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd (WELCURE) trades at ₹0.28 on NSE and BSE. Market cap ₹67.97 (Cr). Educational data only.

What is the P/E ratio of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd has a P/E of 1.98x vs industry average 31.77x.

What is the Bull Run score for Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd has a Bull Run score of 51.9/100 based on 25+ financial parameters.

Does Welcure Drugs & Pharmaceuticals Ltd pay dividends?

Welcure Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd has ROE of 4.18%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.92.

Is Welcure Drugs & Pharmaceuticals Ltd a good investment?

Bull Run gives Welcure Drugs & Pharmaceuticals Ltd a score of 51.9/100. This is not investment advice — consult a SEBI-registered advisor.